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Simple Summary: Chromatin organisation affects gene expression and contributes to carcinogenesis.
Automatic quantification of chromatin heterogeneity can be applied to identify patients with
increased risk of cancer recurrence and death in several cancer types. We aimed to investigate
the prognostic role of diversity of chromatin compartments in relation to chromatin heterogeneity
and as a potential supplement to pathological risk classifications in gynaecological carcinomas.
To this end, we computed the entropy of both chromatin compartment sizes and optical densities
within compartments. In analysis of two cohorts consisting of 1037 patients with gynaecological
carcinoma, we observed a moderately strong correlation between the prognostic value of the entropies
and chromatin heterogeneity. The entropies provided an objective marker, which, integrated with
pathological risk classifications, might possibly contribute to the selection of high-risk stage I
ovarian carcinoma patients for adjuvant chemotherapy and to preoperative identification of low-risk
endometrial carcinoma patients who are candidates for less extensive surgery.
Abstract: Statistical texture analysis of cancer cell nuclei stained for DNA has recently been used to
develop a pan-cancer prognostic marker of chromatin heterogeneity. In this study, we instead analysed
chromatin organisation by automatically quantifying the diversity of chromatin compartments in
cancer cell nuclei. The aim was to investigate the prognostic value of such an assessment in relation
to chromatin heterogeneity and as a potential supplement to pathological risk classifications in
gynaecological carcinomas. The diversity was quantified by calculating the entropy of both chromatin
compartment sizes and optical densities within compartments. We analysed a median of 281 nuclei
(interquartile range (IQR), 273 to 289) from 246 ovarian carcinoma patients and a median of 997 nuclei
(IQR, 502 to 1452) from 791 endometrial carcinoma patients. The prognostic value of the entropies
and chromatin heterogeneity was moderately strongly correlated (r ranged from 0.68 to 0.73), but the
novel marker was observed to provide additional prognostic information. In multivariable analysis
with clinical and pathological markers, the hazard ratio associated with the novel marker was 2.1
(95% CI, 1.3 to 3.5) in ovarian carcinoma and 2.4 (95% CI, 1.5 to 3.9) in endometrial carcinoma.
Integration with pathological risk classifications gave three risk groups with distinctly different
prognoses. This suggests that the novel marker of diversity of chromatin compartments might
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possibly contribute to the selection of high-risk stage I ovarian carcinoma patients for adjuvant
chemotherapy and low-risk endometrial carcinoma patients for less extensive surgery.
Keywords: chromatin compartments; chromatin organisation; texture analysis; prognostic marker;
ovarian cancer; endometrial cancer
1. Introduction
The higher-order chromatin organisation in human cell nuclei has been linked to gene expression
and found to alter during cell differentiation [1,2]. Defects in the higher-order chromatin organisation
can result in human diseases [3]. In human cancer cells, chromatin organisation has been observed to
be a dominant determinant of variation in regional mutation rates [4,5].
Statistical texture analysis of cancer cell nuclei stained for DNA has recently been used to develop
a marker of chromatin heterogeneity that quantifies the level of disorganisation in the chromatin
structure [6]. The marker has been shown to identify patients with increased risk of cancer-specific
death in several cancer types [6] and is externally validated by independent investigators to predict
overall and disease-free survival in colorectal cancer [7].
The marker of chromatin heterogeneity quantifies the chromatin entropy using the extension of
the grey level entropy matrix (GLEM) [8] to four dimensions (GLEM4D) [9]. In the development of the
marker, patterns of aberrant chromatin organisation were identified by mapping subregions of nuclear
images to elements in the GLEM4D and then correlating the frequency of chromatin patterns residing
to a GLEM4D element to the patient outcome observed in the training dataset [6]. This provided a
score quantifying whether and to which extent a chromatin pattern indicates good or poor clinical
outcome, which was used to classify new patients as chromatin homogeneous (CHO) or chromatin
heterogeneous (CHE) [6,7]. As high entropy in subregions of nuclear images was associated with poor
clinical outcome, many interleaved chromatin compartments with different condensations will cause
the patient to be classified as CHE [6]. This indirect analysis of chromatin compartments will however
ignore whether the compartments are more or less similar throughout the nucleus in terms of some
attributes, e.g., volume, number, peripheral localisation or shape.
In this study, we aimed to investigate the prognostic value of a more direct analysis of chromatin
compartments by automatically quantifying the diversity of chromatin compartments in cancer cell
nuclei. As the size and number of chromatin compartments have been observed to vary during
carcinogenesis [10–15], we computed the entropy of chromatin compartment sizes because an increase
in size or number of chromatin compartments is expected to increase this entropy. The entropy was
coupled with the entropy of the measured optical densities within the chromatin compartments,
which suggests the diversity of DNA content in the chromatin compartments of a cancer cell nucleus.
The entropies were computed separately for highly and weakly condensed compartments. The relatively
weakly condensed compartments are assumed to be euchromatic regions that are transcriptionally
active, while the relatively highly condensed compartments are assumed to be inactive, heterochromatic
regions in the nucleus. Adaptive feature values were computed by correlating the entropies with the
clinical outcome after surgical removal of gynaecological carcinomas. The feature values were applied
to develop an objective marker of diversity of chromatin compartments using a set of patients and then
evaluated on another set of patients. The feature values of this novel marker were compared to the
feature value of the marker of chromatin heterogeneity, and we also investigated whether the novel
marker might improve risk stratification of patients with ovarian or endometrial carcinoma.
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2. Materials and Methods
2.1. Patient Cohorts
The first cohort consisted of 246 patients with International Federation of Gynecology and
Obstetrics (FIGO) stage I ovarian carcinoma that were treated during 1982–1989 [16]. All patients had
their ovarian cancer resected in a surgical procedure that involved peritoneal washing, hysterectomy,
bilateral salpingo-oophorectomy and omentectomy. Surgery was generally performed at county
hospitals in Norway and followed by evaluation of further treatment at the Norwegian Radium
Hospital. The FIGO stage was reviewed according to 1988 criteria, albeit lymphadenectomy was not
routinely performed. All patients provided informed consent, and the study was in accordance with
Norwegian law.
A cohort of 791 consenting patients from the multicentre trial Molecular Markers in Treatment of
Endometrial Cancer (MoMaTEC) (clinical trial identifier NCT00598845) were prospectively included in
this study [17]. These patients were treated for endometrial carcinoma between 2001 and 2011 and
staged according to 2009 criteria [18]. The Regional Committees for Medical and Health Research
Ethics (REK) in Norway approved the study (REKIII no. 052.01).
Each patient cohort was divided into a train subset and a test subset, and it was verified that
the subsets were roughly balanced on surgery date and important clinical parameters. The subsets
were the same as in previous studies that analysed the same patient cohorts [9,19]. In the ovarian
carcinoma cohort, the train subset consisted of 134 patients and the test subset of 112 patients [9].
In the endometrial carcinoma cohort, the train subset consisted of 398 patients and the test subset of
393 patients [19].
The definition of dichotomous clinical outcome also followed the previous studies [9,19].
For ovarian carcinoma patients, poor outcome was defined as recurrence or cancer-specific death
within ten years after surgery. Those who survived ten years without recurring were defined as having
good outcome. For endometrial cancer patients, poor outcome was defined as cancer-specific death,
and all other patients were defined as having good outcome. There were 72 poor outcome patients in
the ovarian carcinoma cohort (37 in the train subset and 35 in the test subset) and 84 in the endometrial
carcinoma cohort (44 in the train subset and 40 in the test subset).
2.2. Sample Preparation
Tissue samples of the resected ovarian tumours and of curettage specimens from the endometrial
carcinoma patients were analysed. First, the samples were fixed in 4% buffered formaldehyde and
paraffin-embedded (FFPE). A pathologist selected a representative region for each tumour using
haematoxylin and eosin-stained sections. One or more 50 µm sections of each selected tumour region
were enzymatically digested (SIGMA protease, type XXIV, Sigma Chemical C., St. Louis, MO, USA)
to isolate the cell nuclei. The nuclei were stained by Feulgen-Schiff according to an established
protocol [20], and thus exclusively highlighting DNA.
The stained nuclei were imaged by a Zeiss Axioplan light microscope equipped with a Zeiss
objective lens (40×magnification, 0.75 numerical aperture), a 546 nm green filter and a black-and-white
high-resolution digital camera (C4742-95, Hamamatsu Photonics, Hamamatsu, Japan, was used for the
ovarian carcinoma material and AxioCam MrM, Zeiss, Jena, Germany, for the endometrial carcinoma
material), providing a depth of field of about 1.5 µm and a physical resolution of about 165 nm per
pixel. The images were stored with 10 bits pixel depth and corrected for background effects by utilising
an image acquired from an empty region on the slide.
Subimages of whole, isolated, and epithelial cell nuclei were selected by trained personnel for
the ovarian carcinoma patients and segmented using a manually chosen global threshold. For the
endometrial carcinoma patients, segmentation of each nucleus from the background was completed
automatically using the Ploidy Work Station (Room4, Sussex, UK). This software was also used
to automatically discard non-intact nuclei (e.g., cut, folded, or connected), necrotic nuclei and
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non-epithelial nuclei for the endometrial carcinoma patients. Trained personnel verified the automatic
nucleus classifications. Any holes in the segmentation mask of a nucleus were removed. The images of
the included segmented nuclei are subsequently referred to as nuclear images. These are the same as
analysed previously [6]. Figure 1A shows a few examples of nuclear images.
The median number of nuclear images was 281 (interquartile range (IQR), 273 to 289) for an
ovarian carcinoma patient, and the median number of nuclear pixels in each image was about 3600
(IQR, 2700 to 4600). There was a median of 997 (IQR, 502 to 1452) nuclear images for each endometrial
carcinoma patient, with a median size of about 4100 (IQR, 3200 to 5100) pixels. In total, 840,000 nuclear
images were analysed.
2.3. Quantification of Diversity of Chromatin Compartments
2.3.1. Segmentation of Chromatin Compartments
In order to segment chromatin compartments in the nuclear images, we generalised Niblack’s
adaptive thresholding algorithm [21] and applied a metric inspired by Yanowitz and Bruckstein’s
validation step [22] to automatically label each pixel as one of three categories based on the optical
density of the pixel and the optical densities of nearby pixels. Section S1 in the Supplementary
Materials describes relevant details, and Figure 1B illustrates some segmentation examples. The three
categories were termed dark, grey, and bright. Regions labelled as dark or bright corresponded to
relatively highly or relatively weakly condensed chromatin compartments, respectively, possibly
heterochromatin and euchromatin. Pixels with intermediate optical densities were labelled grey
and not analysed directly. The inclusion of this category facilitated separation of highly and weakly
condensed compartments from the average optical density of nearby pixels, as opposed to separating
highly and weakly condensed compartments from each other.
2.3.2. Analysis of Chromatin Compartments
The size of a chromatin compartment was measured as the number of pixels in the segmented
region, and the distribution of sizes in a nuclear image was found separately for dark regions and
bright regions (Figure 1C). Similarly, the distribution of optical densities within dark regions and bright
regions was found (Figure 1C). The entropy of each distribution was computed and then summed,
resulting in a continuous value that described the diversity of either highly or weakly condensed
chromatin compartments in the nucleus. Details of the computation are described in Section S2
in the Supplementary Materials, which is placed in the context described by Maître et al. [23] and
Tupin et al. [24].
2.3.3. Dual Entropy Sum Histogram
The entropy sum of each nuclear image was adaptively quantified separately for the dark and
bright regions (see Section S4 in the Supplementary Materials for details). The resulting distributions
of entropy sums for a patient are two sum histograms [25] (Figure 1D), which encapsulate information
about the diversity of chromatin compartments in its cancer cell nuclei. We denoted each distribution
as a dual entropy sum histogram (DESH) and represented each patient by the DESH of dark regions
and the DESH of bright regions.
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Figure 1. Pipeline for assessing the marker of diversity of chromatin compartments. (A) Tumour cell
nuclei from a formalin-fixed and paraffin-embedded (FFPE) block are imaged by a microscope. (B) The
segmentation algorithm automatically finds dark (shown in cyan) and bright (shown in light brown)
regions, corresponding to relatively highly and relatively weakly condensed chromatin compartments,
respectively. (C) The histogram of chromatin compartment sizes and the histogram of optical densities
in the compartments are computed separately for the dark and bright regions in the nuclear image.
The entropy of each histogram is then summed, giving a single continuous value that describes the
diversity of dark chromatin compartments in the nuclear image, and similarly a value that describes
the bright chromatin compartments. (D) The entropy sums of a patient’s nuclear images provide
the dual entropy sum histogram (DESH) of the dark regions and the DESH of the bright regions.
(E) The two adaptive DESH features are computed, one from each DESH. The classification of a
patient, as having either diverse chromatin compartments (DCC) or similar chromatin compartments
(SCC), is determined by comparing the two features to the decision line. DCC, diverse chromatin
compartments; DESH, dual entropy sum histogram; FFPE, formalin-fixed and paraffin-embedded;
SCC, similar chromatin compartments.
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2.3.4. Marker of Diversity of Chromatin Compartments
Using an established adaptive feature extraction method initiated by Walker et al. [26] and later
developed by Albregtsen et al. [27–30], a single continuous value was computed from each DESH
(see Section S3 in the Supplementary Materials for details). To simplify the two DESH features of
a patient into an assessment of diverse vs. similar chromatin compartments, we tested a series of
classification methods in the training subset of the ovarian carcinoma cohort, including parametric
methods assuming Gaussian distributions, non-parametric methods such as Parzen window and k
nearest neighbour, and support vector machines (SVMs), both linear SVM and with the Gaussian
radial basis function. It appeared that the most prognostic classifier was produced by assuming equal
prior probabilities and a Gaussian feature distribution in each outcome class with common covariance
matrix. This simple and robust classification method [31,32] was therefore utilised to define a marker
of diversity of chromatin compartments in both training subsets (Figure 1E). Figure 1 illustrates the
major steps involved in assessing the novel marker for a new patient. Through the quantification of
diversity of chromatin compartments in each patient’s tumour nuclei, the marker classifies the patient
as having either diverse chromatin compartments (DCC) or similar chromatin compartments (SCC),
indicating poor or good clinical outcome, respectively.
2.4. Statistical Analyses
Sensitivity and specificity on the test subset were calculated using the same definition of
dichotomous clinical outcome as used for training. The classification accuracy was mainly measured
in terms of the balanced correct classification rate (BCCR), i.e., the mean of sensitivity and specificity.
This metric is also known as balanced accuracy and better describes a classifier’s ability to distinguish
outcome groups of substantially different sizes than the ordinary correct classification rate (CCR).
Survival analyses were performed using the same clinical outcomes as end points, but without the
dichotomisation. The end points were defined as proposed by Punt et al. [33] and the same as in
previous studies that analysed the same cohorts [9,19]. Specifically, time to recurrence was analysed
for ovarian carcinoma patients and calculated from surgery to recurrence or 31st of December 1998.
Cancer-specific survival was analysed for endometrial carcinoma patients and calculated from surgery
to death from endometrial carcinoma or end of follow-up. Survival analyses were performed using
the Cox proportional hazards model and Wald χ2 test, except for univariable survival analyses of
categorical markers, which were performed using the log-rank test. The variables included in the
multivariable models were the same as in previous studies that have analysed the same cohorts.
Specifically, the multivariable analysis of ovarian carcinoma patients was adjusted for FIGO stage (IB or
IC vs. IA) and histological grade (grade 3 or clear cell vs. grade 1 or 2) [6,9,16,34], while the multivariable
analysis of endometrial carcinoma patients was adjusted for the preoperatively available markers age
(continuous) and pathological risk classification (high-risk vs. low-risk) [6,19,34]. The pathological risk
classification was based on the curettage histology report and assigned benign, experiencing hyperplasia
or endometrioid grade 1 or 2 tumours as low-risk, while other tumours (i.e., endometrioid grade 3 or
non-endometrioid) were assigned as high-risk [17]. Patients with missing data for variables included in
a particular analysis were excluded from that analysis. A two-sided p < 0.05 was considered statistically
significant. Texture and survival analyses were performed in MATLAB R2012b (The MathWorks,
Natick, MA, USA) and Stata/SE 16.1 (StataCorp, College Station, TX, USA), respectively.
2.5. Data Availability Statement
Restrictions apply to the availability of the data presented in this study because patients did not
provide permission for data sharing outside the institution or established collaborations.
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3. Results
3.1. Patient Characteristics
Characteristics of the studied patients are presented in Tables S1 and S2. In the ovarian carcinoma
cohort, 37% patients were classified as having DCC and 31% patients were classified as CHE. In the
endometrial carcinoma cohort, 24% patients were classified as having DCC and 15% patients were
classified as CHE. The median follow-up time was 11.7 (IQR, 8.3 to 13.6) years for the ovarian carcinoma
patients, while it was 2.96 (IQR, 1.47 to 4.44) years for the endometrial carcinoma patients.
3.2. Size and Number of Chromatin Compartments
Patients with poor clinical outcome typically had more chromatin compartments per tumour cell
nucleus than patients with good clinical outcome (Figure S1). Additionally, the segmented chromatin
compartments were on average larger in patients with poor clinical outcome compared to patients
with good clinical outcome (Figure S2). The same trends were observed for the relatively highly and
the relatively weakly condensed compartments, i.e., the dark and the bright regions, respectively
(Figures S2 and S3).
3.3. Relative Prognostic Value of Markers of Chromatin Entropy
The markers of chromatin entropy, e.g., chromatin heterogeneity and diversity of chromatin
compartments, obtain their assessment from feature values that quantify prognostic indications on a
continuous scale. The feature value of the marker of chromatin heterogeneity and the feature values of
the marker of diversity of chromatin compartments were moderately strongly correlated in both test
subsets (Figure 2). Similar correlations were also observed in the entire patient cohorts. In the ovarian
carcinoma cohort, Pearson correlation coefficient was 0.68 (95% CI, 0.61 to 0.74) and 0.71 (95% CI, 0.64 to
0.76) when applying the feature value of the dark and bright regions, respectively. In the endometrial
carcinoma cohort, Pearson correlation coefficient was 0.73 (95% CI, 0.70 to 0.76) and 0.73 (95% CI,
0.69 to 0.76) when applying the feature value of the dark and bright regions, respectively. In terms of
classification, 417 (83%) of the 505 patients in the test subsets had tumours with either both SCC and
CHO or both DCC and CHE. Only 21 (4%) had tumours with both SCC and CHE, while 67 (13%) had
tumours with both DCC and CHO.
3.4. Classification Performance
The marker of diversity of chromatin compartments obtained a BCCR of 67% on both test subsets.
This is four to five percentage points better than the marker of chromatin heterogeneity (Table 1).
For reference, Table 1 also specifies performance estimates of the GLEM4D-based classifiers that were
trained and tested by Nielsen et al. [9] and Hveem et al. [19] using the same train and test subsets as in
the present study. Compared to these cancer type specific markers, the marker of diversity of chromatin
compartments provided a two to three percentage points better BCCR on both test subsets (Table 1).
Similar trends were observed for the train subsets (Table 1). All markers performed slightly better on
the train subsets than the test subsets (Table 1), even though the marker of chromatin heterogeneity
did not utilise the train subsets for training. Scatter plots of the two feature values of the marker of
diversity of chromatin compartments illustrate good separation of the clinical outcome classes in both
train and test subsets (Figure S3).
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Figure 2. Scatter plots of the chromatin value, i.e., feature value of the marker of chromatin heterogeneity,
and the feature values of the marker of diversity of chromatin compartments. (A) The chromatin
value vs. the DESH feature value of dark regions in the test subset of the ovarian carcinoma cohort.
Pearson correlation coefficient was 0.64 (95% CI, 0.51 to 0.74). (B) The chromatin value vs. the DESH
feature value of dark regions in the test subset of the endometrial carcinoma cohort. Pearson correlation
coefficient was 0.73 (95% CI, 0.68 to 0.77). (C) The chromatin value vs. the DESH feature value of bright
regions in the test subset of the ovarian carcinoma cohort. Pearson correlation coefficient was 0.65
(95% CI, 0.52 to 0.74). (D) The chromatin value vs. the DESH feature value of bright regions in the test
subset of the endometrial carcinoma cohort. Pearson correlation coefficient was 0.70 (95% CI, 0.64 to
0.75). DESH, dual entropy sum histogram.
Table 1. Classification performance of markers of chromatin entropy.
Ovarian Carcinoma Endometrial Carcinoma
Marker Set BCCR CCR Sens. Spec. BCCR CCR Sens. Spec.
Diversity of chromatin compartments
Train 71.7% 72.4% 70.3% 73.2% 67.5% 77.6% 54.5% 80.5%
Test 66.8% 69.9% 57.1% 76.5% 66.9% 76.3% 55.0% 78.8%
All 69.2% 71.3% 63.9% 74.5% 67.2% 77.0% 54.8% 79.6%
Chromatin heterogeneity
Train 65.7% 70.9% 54.1% 77.3% 64.0% 81.9% 40.9% 87.0%
Test 63.2% 67.0% 51.4% 75.0% 61.8% 83.2% 35.0% 88.7%
All 64.6% 69.2% 52.8% 76.4% 63.0% 82.6% 38.1% 87.8%
GLEM4D (for specific cancer type)
Train 70.1% 72.4% 64.9% 75.3% 66.0% 74.9% 54.5% 77.4%
Test 63.9% 68.0% 51.4% 76.5% 64.5% 72.0% 55.0% 73.9%
All 67.0% 70.5% 58.3% 75.8% 65.2% 73.5% 54.8% 75.7%
BCCR, balanced correct classification rate; CCR, correct classification rate; GLEM4D, four-dimensional grey level
entropy matrix.
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3.5. Survival Analyses of Entire Cohorts
Kaplan–Meier survival curves according to the marker of diversity of chromatin compartments
are shown in Figure 3A,B. Estimated 10 year recurrence-free survival was 83% (95% confidence interval
(CI), 76% to 88%) for ovarian carcinoma patients classified as having SCC and 49% (95% CI, 38% to
59%) for ovarian carcinoma patients classified as having DCC. For endometrial carcinoma patients,
estimated 5 year cancer-specific survival was 91% (95% CI, 87% to 94%) for tumours with SCC and
67% (95% CI, 58% to 75%) for tumours with DCC.
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Figure 3. (A) Kaplan–Meier curves by marker of diversity of chromatin compart ents in the ovarian
carcinoma cohor . (B) Kaplan–Meier curves by marker of dive sity of ch omatin c partments in
the endometrial carcinoma cohort. (C) Kaplan–Meier curves by marker of diversity of chromatin
compartments and pathological risk classification in the ovarian carcinoma cohort. Pathological
high-risk tumours were defined as those with either clear cell histology, poor differentiation or
both moder te differ ntiation and International Federation of Gyne ol gy and Obstetrics (FIGO)
stage IB or IC, while other tumours were defined as low or medium risk [35]. (D) Kaplan–Meier
curves by marker of diversity of chromatin compartments and pathological risk classification in the
endometrial carcin ma cohort. Pathological high-risk tumours were defined as those assessed as
non-endometrioid or endometrioid grade 3 using the curettage specimens, while low-risk if benign,
experiencing hyperplasia or endometrioid grade 1 or 2 [17]. DCC, diverse chromatin compartments;
HPR, pathological risk classification was high; LPR, pathological risk classification was low (or medium);
SCC, similar chromatin compartments.
The hazard ratio (HR) of recurring ovarian cancer was nearly four times higher for tumours with
DCC compared to tumours with S (Table 2), and the HR of endome rial canc r-specific mortality was
close to five times higher (Table 3). In both cohorts, the marker of diversity of chromatin compartments
was significantly associated with clinical outcome after also adjusting for established clinical and
pathological markers (Tables 2 and 3). The adjusted HR of ovarian cancer recurrence and endometrial
cancer-specific mortality was more than twice for tumours with DCC compared to tumours with
SCC (Tables 2 and 3). When nalysing only the 767 endometrial carcinoma patients treated with
hysterectomy, the HR was 5.2 (95% CI, 3.2 to 8.3) in univariable analysis and 3.1 (95% CI, 1.8 to 5.3) in
multivariable analysis.
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Table 2. Analyses of time to recurrence for patients with ovarian carcinoma.
Univariable Analysis Multivariable Analysis
Marker Variable Treatment HR (95% CI) p Value HR (95% CI) p Value
Diversity of chromatin compartments DCC vs. SCC 3.8 (2.4–6.1) <0.001 2.1 (1.3–3.5) 0.004
FIGO stage IB or IC vs. IA 2.6 (1.5–4.7) 0.001 2.1 (1.2–3.8) 0.014
Histological grade Grade 3 or clear cell vs. Grade 1 or 2 5.6 (3.3–9.6) <0.001 4.0 (2.2–7.1) <0.001
CI, confidence interval; DCC, diverse chromatin compartments; FIGO, International Federation of Gynecology and
Obstetrics; HR, hazard ratio; SCC, similar chromatin compartments.
Table 3. Analyses of cancer-specific survival for patients with endometrial carcinoma.
Univariable Analysis Multivariable Analysis
Marker Variable Treatment HR (95% CI) p Value HR (95% CI) p Value
Diversity of chromatin compartments DCC vs. SCC 4.7 (3.0–7.2) <0.001 2.4 (1.5–3.9) 0.001
Pathological risk classification High risk vs. Low risk 5.8 (3.8–9.0) <0.001 3.3 (2.0–5.4) <0.001
Age at primary treatment 1-year increment 1.06 (1.04–1.09) <0.001 1.05 (1.03–1.07) <0.001
CI, confidence interval; DCC, diverse chromatin compartments; HR, hazard ratio; SCC, similar
chromatin compartments.
3.6. Survival Analyses in Subgroups of Chromatin Heterogeneity
In each patient cohort, the marker of diversity of chromatin compartments provided additional
prognostic information in patients with CHO tumours (Figures 4 and 5). The HR was 4.8 (95% CI,
2.5 to 9.5) and 2.6 (95% CI, 1.4 to 4.8) in the CHO subgroup of the ovarian and endometrial carcinoma
cohort, respectively, and 5.2 (95% CI, 2.0 to 13.6) and 2.6 (95% CI, 1.1 to 6.0) in the corresponding test
subsets. The marker of diversity of chromatin compartments was not significant in ovarian carcinoma
patients with CHE tumours (Figure 4), but significant in endometrial carcinoma patients with CHE
tumours (Figure 5).
Cancers 2020, 12, x FOR PEER REVIEW 11 of 18 
 
CI, confidence interval; DCC, diverse chromatin compartments; HR, hazard ratio; SCC, similar 
chromatin compartments. 
3.6. Survival Analyses in Subgroups of Chromatin Heterogeneity 
In each patient cohort, the marker of diversity of chromatin compartments provided additional 
prognostic information in patients with CHO tumours (Figures 4 and 5). The HR was 4.8 (95% CI, 2.5 
to 9.5) and 2.6 (95% CI, 1.4 to 4.8) in the CHO subgroup of the ovarian and endometrial carcinoma 
cohort, respectively, and 5.2 (95% CI, 2.0 to 13.6) and 2.6 (95% CI, 1.1 to 6.0) in the corresponding test 
subsets. The marker of diversity of chromatin compartments was not significant in ovarian carcinoma 
patients with CHE tumours (Figure 4), but significant in endometrial carcinoma patients with CHE 
tumours (Figure 5). 
 
Figure 4. Forest plot illustrating the hazard ratio and 95% confidence interval of the marker of 
diversity of chromatin compartments in subgroups of patients with ovarian carcinoma. Pathological 
high-risk tumours were defined as those with either clear cell histology, poor differentiation or both 
moderate differentiation and FIGO stage IB or IC, while other tumours were defined as low or 
medium risk [35]. GLEM4D classifications refer to the marker trained and tested by Nielsen et al. [9] 
using the same ovarian carcinoma cohort as the marker of diversity of chromatin compartments. 
FIGO, International Federation of Gynecology and Obstetrics; GLEM4D, four-dimensional grey level 
entropy matrix. 
Figure 4. Forest plot illustrating the hazard ratio and 95% confidence interval of the marker of diversity
of chromatin compartments in subgroups of patients with ovarian ca c noma. Path logical high-risk
tumours were defined as those with either clear cell histology, poor differentiation or both moderate
differentiation and FIGO stage IB or IC, while other tumours were defined as low or medium risk [35].
GLEM4D classifications refer to the marker trai ed and tested by Nielsen et al. [9] using the same
ovarian carcinoma cohort as the marker of diversity of chromatin compartments. FIGO, International
Federation of Gynecology and Obstetrics; GLEM4D, four-dimensional grey level entropy matrix.
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Figure 5. Forest plot illustrating the hazard ratio and 95% confidence interval of the marker of diversity
of chromatin compartments in subgroups of patients with endometrial carcinoma. Pathological
high-risk tumours were defined as those assessed as non-endometrioid or endometrioid grade 3 using
the curettage specimens, while low-risk if benign, experiencing hyperplasia or endometrioid grade 1 or
2 [17]. The hazard ratio is not depicted for the subgroup of patients with chromatin heterogeneous
tumours because no cancer-specific death occurred among the 26 patients classified as having similar
chromatin compartments, and thus the estimated hazard ratio approached infinity (there were 32 events
among the 92 patients classified as having diverse chromatin compartments). GLEM4D classifications
refer to the marker trained and tested by Hveem et al. [19] using the same endometrial carcinoma cohort
as the marker of diversity of chromatin compartments. FIGO, International Federation of Gynecology
and Obstetrics; GLEM4D, four-dimensional grey level entropy matrix.
When analysing a multivariable model consisting of the two markers of chromatin entropy, the HR
of tumours with DCC compared to tumours with SCC was 3.1 (95% CI, 1.7 to 5.7) in the ovarian
carcinoma cohort and 3.3 (95% CI, 1.9 to 5.6) in the endometrial carcinoma cohort. In these multivariable
analyses, the marker of chromatin heterogeneity was not significant in the ovarian carcinoma cohort
(HR = 1.36; 95% CI, 0.76 to 2.44; p = 0.29), but was significant in the endometrial carcinoma cohort
(HR = 2.0; 95% CI, 1.2 to 3.5; p = 0.012). Analysing only endometrial carcino a patients treated
with hysterectomy slightl increased the prognostic difference between the two markers; HR was 3.8
(95% CI, 2.2 to 6.8) for tumours with DCC compared to umours with SCC, while 1.8 (95% CI, 1.0 to 3.3)
for CHE tumours compared to CHO t mours.
For reference, the corresponding comparisons were performed for the GLEM4D-based clas ifiers
that were trained and test by Nielsen et al. [9] and Hveem et al. [19] using the same tr in and test
subsets as used for the marker of diversity of chromatin co partments. Similar trends and identical
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assessments of statistical significance were observed for the cancer type specific GLEM4D-based markers
as for the pan-cancer marker of chromatin heterogeneity, both in subgroup analyses (Figures 4 and 5)
and in multivariable analyses with the marker of diversity of chromatin compartments.
3.7. Survival Analyses in Subgroups of Clinical and Pathological Markers
The relation to clinical and pathological risk factors could be better understood by analysing
the marker of diversity of chromatin compartments in the subgroups defined by another patient
characteristic. The forest plots in Figures 4 and 5 indicate that the marker of diversity of chromatin
compartments might have prognostic value in most of the analysed subgroups, albeit statistical
significance was not consistently observed in subgroups with relatively few patients or events. Highest
HRs were often observed in subgroups associated with low or medium risk, e.g., in terms of FIGO
stage, histological grade or pathological risk classification.
When stratified on pathological risk classification, the HR of tumours with DCC compared to
tumours with SCC was nearly two in analysis of the subgroup of patients classified as having high
pathological risk (HPR) (Figures 4 and 5). The prognostic value appeared higher in patients classified as
having low pathological risk (LPR), where the HR associated with the marker of diversity of chromatin
compartments was about five (Figures 4 and 5). We integrated the two markers into a three-category
risk stratification by defining low-risk tumours as those with both SCC and LPR, high-risk tumours as
those with both DCC and HPR, and medium-risk tumours as those where the two markers indicated
different prognoses. This three-level categorisation appeared to encapsulate the prominent survival
differences identified by the two individual markers (Figure 3C,D). Distinctly different prognoses
were observed in the three risk groups. The estimated 10 year recurrence-free survival of ovarian
carcinoma patients was 95% (95% CI, 88% to 98%) in the low-risk group, 67% (95% CI, 55% to 76%) in
the medium-risk group, and 42% (95%, 31% to 53%) in the high-risk group. Similarly, the estimated
5 year endometrial cancer-specific survival was 93% (95% CI, 90% to 96%) in low-risk, 76% (95% CI,
67% to 83%) in medium-risk, and 55% (95% CI, 40% to 68%) in high-risk. The survival estimates
were slightly higher when excluding endometrial carcinoma patients not treated with a hysterectomy,
becoming 94% (95% CI, 90% to 96%) in low-risk, 79% (95% CI, 70% to 86%) in medium-risk, and 58%
(95% CI, 42% to 71%) in high-risk.
Stage I endometrial carcinoma patients may post-surgically be risk stratified based on histological
type and grade, substage and lymphovascular space invasion status [36]. In stage I patients classified
as high-risk, the 51 patients with DCC had an estimated 5 year endometrial cancer-specific survival
of 69% (95% CI, 51% to 82%), compared to 98% (95% CI, 86% to 100%) for the 47 patients in this
subgroup with SCC. The corresponding HR was 11.4 (95% CI, 1.5 to 87.6). Only 10 (2%) cancer-specific
deaths were observed for the 508 stage I patients with low, intermediate, or high-intermediate risk.
For these patients, the estimated 5 year endometrial cancer-specific survival was 95% (95% CI, 81%
to 99%) for the 65 patients with DCC and 97% (95% CI, 94% to 99%) for the 443 patients with SCC.
The corresponding HR was 2.24 (95% CI, 0.46 to 10.80).
4. Discussion
We applied texture analysis methods to analyse the chromatin compartments in cancer cell nuclei
and automatically quantify the diversity of chromatin compartments in each nucleus. In patients
with gynaecological carcinomas, poor clinical outcome was observed to be associated with both more
and larger chromatin compartments than good clinical outcome. This finding in established cancer
extends previous reports on the changes in size and number of chromatin compartments that occur
during carcinogenesis [10–15]. We observed the increase in number and size for both the relatively
highly and the relatively weakly condensed compartments, suggesting that poor clinical outcome
is associated with cancer cell nuclei where the chromatin is more segregated into heterochromatic
and euchromatic regions, as opposed to being a mixture of the two. The entropy of the compartment
sizes and the entropy of the optical densities within compartments were utilised by robust machine
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learning algorithms to obtain a marker of diversity of chromatin compartments. The marker accurately
predicted ovarian cancer recurrence and endometrial cancer-specific mortality, providing HRs of about
four and a mean of sensitivity and specificity of 67% on test subsets, which further suggests that
diversity of chromatin compartments is a characteristic of poor prognosis.
The pan-cancer marker of chromatin heterogeneity applied a purely statistical texture analysis
method to identify chromatin patterns associated with poor clinical outcome [6] and could potentially
be applicable to guide the selection of adjuvant treatments in a range of cancer types [37]. The combined
structural and statistical texture analysis method applied by the marker of diversity of chromatin
compartments provides a different approach to quantify chromatin entropy. The prognostic value
of the novel marker correlated moderately strongly with the prognostic value of the marker of
chromatin heterogeneity, but the novel marker was also observed to provide additional prognostic
information. Moreover, the marker of diversity of chromatin compartments appeared to provide
prognostic information supplementary to established prognostic factors. Subgroup analyses suggested
that the added prognostic information was largest in patient groups associated with low or medium
risk in terms of pathological markers.
In the clinic, multiple prognostic factors are often applied to inform the discussion with patients on
the risks and benefits of different options for adjuvant treatment. In ovarian carcinoma, chemotherapy is
generally recommended in stage II to IV, while no adjuvant chemotherapy, platinum-based monotherapy
or combination chemotherapy may all be appropriate options in stage I [38]. The analysed pathological
risk classification for stage I ovarian carcinoma combines FIGO substage and histological grade [35],
and the resulting high-risk patients have been shown to benefit from adjuvant chemotherapy [39].
In our patient cohort, 10 year recurrence-free survival of ovarian carcinoma was 53% if labelled high-risk
by the pathological risk classification and otherwise 91%. This survival difference is comparable
with that of the marker of diversity of chromatin compartments, and the two markers each provided
supplementary prognostic information that allowed integration into a three-category risk assessment.
The finer risk stratification observed with this novel categorisation suggests that it could possibly be
used to inform the discussion of adjuvant treatment with patients with stage I ovarian carcinoma.
Further investigations are warranted to assess the effect of adjuvant treatment on these risk groups.
The high accuracy of the marker of diversity of chromatin compartments on the endometrial
carcinoma cohort shows that the marker can be reliably assessed using curettage specimens, not only
when using resection specimens, which were used for the ovarian carcinoma cohort. The possibility
to preoperatively risk-stratify patients could reduce morbidity from extensive surgery of low-risk
endometrial cancer patients [40] and could also indicate the viability of fertility-sparing surgery.
The novel marker provided prognostic information supplementary to the pathological risk classification
based on the curettage histology. Integration of the two markers provided a three-category risk
assessment, which was observed to identify endometrial carcinoma patients with distinctly different
probabilities of cancer-specific survival. The consequence of using this risk stratification to guide the
choice of surgical procedure may be assessed in a randomised controlled trial.
About 80% of endometrial cancer patients are diagnosed with FIGO stage I tumours [36].
The recommendations of adjuvant treatment for these patients range from no adjuvant treatment
and only vaginal cuff brachytherapy to complete pelvic radiation and possibly chemotherapy [36,41].
In particular, vaginal cuff brachytherapy or pelvic radiation has been recommended for patients
classified as high-risk (i.e., endometrioid stage IB grade 3 or non-endometrioid stage I), and adjuvant
chemotherapy may also be considered or recommended if no surgical nodal staging was performed or
the tumour is non-endometrioid [36,41]. The marker of diversity of chromatin compartments appeared
strongly prognostic in this patient subgroup. The excellent cancer-specific survival rate observed for
the patients in this subgroup with SCC suggests that adjuvant treatment might not be needed for these
patients, which would spare patients from the associated morbidities, while the low survival rate
observed for the corresponding patients with DCC suggests that it might be appropriate to offer these
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patients adjuvant chemotherapy. This interesting finding warrants further investigations, in particular
in a randomised controlled trial to assess its clinical utility.
5. Conclusions
We developed a novel marker of diversity of chromatin compartments by segmenting and
analysing the chromatin compartments in nuclei from gynaecological carcinomas. Patients with poor
clinical outcome were associated with both more and larger chromatin compartments than patients
with good clinical outcome. The marker correlated with the marker of chromatin heterogeneity
but was observed to provide prognostic information supplementing chromatin heterogeneity and
other prognostic markers. Integration with pathological risk classification provided three patient
groups associated with substantially different risks of ovarian cancer recurrence and endometrial
cancer-specific mortality. Clinical application of the novel risk assessments might be used to tailor
surgical and adjuvant treatments to individual gynaecological carcinoma patients. This could possibly
reduce overtreatment of low-risk patients and facilitate more comprehensive adjuvant treatments to be
offered to high-risk patients. However, randomised controlled trials must first be conducted to assess
the efficacy of treatments in the different risk groups.
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